8-K: cbdMD Acquires Bluebird Botanicals, Expands CBD Portfolio

cbdMD, Inc. has acquired substantially all assets of Gaia Botanicals, LLC, including the Bluebird Botanicals brand, for common stock and an earnout, expanding its CBD product offerings.

Summary

• cbdMD, Inc. acquired substantially all assets of Gaia Botanicals, LLC (d/b/a Bluebird Botanicals), CBD CliniLabs LLC, and Precision Botanical LLC.
• Acquired assets include the Bluebird Botanicals brand name, online CBD marketplace, related trademarks, inventory, and certain other assets.
• cbdMD assumed certain specified liabilities of Gaia Botanicals.
• The consideration for the acquisition includes 425,000 restricted shares of cbdMD common stock issued at closing.
• An earnout of up to 525,000 additional restricted shares of cbdMD common stock is contingent on achieving specific Net Revenue targets over a one-year period following the closing date.
• Earnout shares are tiered based on Net Revenue: 525,000 shares for $2,900,000+; 425,000 shares for $2,700,000-$2,900,000; 315,000 shares for $2,500,000-$2,700,000; 185,000 shares for $2,300,000-$2,500,000; 75,000 shares for $2,000,000-$2,300,000; and no earnout below $2,000,000.
• All shares issued (initial and earnout) are subject to a 180-day lock-up period, followed by a 365-day 'dribble out' period limiting sales to an aggregate of 125,000 shares per calendar quarterly period.
• cbdMD committed to spending at least $90,000 per quarter for marketing, advertising, and online traffic related expenses for the Bluebird Brand, subject to reasonable business judgment and market/regulatory conditions.
• cbdMD will provide employment offers to all five active employees of Gaia Botanicals.
• Gaia Botanicals repaid a $200,000 Member Loan prior to or at closing.
• Seller (Gaia Botanicals) and Brandon Beatty (CEO) are subject to a five-year non-compete, non-solicitation, and non-disparagement agreement.

Sentiment

Score: 7

Explanation: The acquisition of an established brand with an earnout structure and marketing commitment is a positive strategic move for cbdMD, indicating growth potential. However, the dilution risk from share issuance and the contingency of the earnout on revenue targets introduce some uncertainty.

Positives

• Acquisition of the established Bluebird Botanicals brand and its online CBD marketplace, expanding cbdMD's product portfolio to include gummies, oils, soft gels, creams, and pet products.
• The earnout structure aligns the seller's incentives with the future revenue performance of the acquired business, potentially driving growth.
• cbdMD committed to a minimum quarterly marketing spend of $90,000 for the Bluebird Brand, indicating a strategic investment to rebuild and grow revenues.
• The inclusion of a five-year non-compete, non-solicitation, and non-disparagement agreement with the seller and its CEO, Brandon Beatty, protects cbdMD's investment and market position.
• Acquisition includes valuable intellectual property assets such as trademarks, domain names, and customer lists.

Negatives

• The issuance of up to 950,000 restricted common shares (425,000 initial + 525,000 earnout) could lead to future dilution for existing cbdMD shareholders if earnout targets are met and shares are sold after the lock-up period.
• The earnout is contingent on achieving specific Net Revenue targets, which are not guaranteed and introduce performance risk.
• cbdMD's marketing commitment for the Bluebird Brand is subject to 'reasonable business judgment' and market/regulatory conditions, potentially allowing for reduced spend if conditions are unfavorable.
• Buyer assumes certain specified liabilities of the acquired entities.

Risks

• Failure to achieve the specified Net Revenue targets for the earnout could result in the seller receiving fewer shares and indicate underperformance of the acquired assets.
• Market, regulatory conditions, or business performance may lead to adjustments in cbdMD's marketing obligations for the Bluebird Brand, potentially impacting its growth trajectory.
• Integration risks associated with combining the acquired assets and operations of Gaia Botanicals into cbdMD's existing business structure.
• Potential for dilution of existing shareholder value due to the issuance of new common stock as consideration.
• Reliance on the continued operation and growth of the Business platform, including www.bluebirdbotanicals.com and other Bluebird related domains and channels.

Future Outlook

cbdMD aims to integrate the Bluebird Botanicals brand and its assets to rebuild and grow revenues, committing to a minimum quarterly marketing spend. The earnout structure incentivizes the acquired business to achieve specific Net Revenue targets over the next year, indicating an expectation of growth in the acquired channels.

Management Comments

• Buyer agrees to act in good faith, in accordance with all Legal Requirements and operate the Business in a manner that is not designed or intended to impede or interfere with, and it agrees that it will not take, cause to be taken, or fail to take or cause to be taken, any action that has the intent of impeding or interfering with the attainment of the Earnout Shares.
• cbdMD's marketing obligations shall be subject to its reasonable business judgment and may be adjusted if market, regulatory conditions, or business performance warrant such adjustment.

Industry Context

This acquisition reflects a potential strategy within the evolving CBD industry for established players like cbdMD to consolidate market share by acquiring recognized brands with existing online marketplaces and customer bases. The focus on expanding product offerings and committing to marketing spend suggests a competitive environment where brand recognition and direct-to-consumer channels are crucial for growth.

Related Party Transactions

• Repayment of a $200,000 Member Loan by Gaia Botanicals (Seller) prior to or at closing.
• Brandon Beatty (CEO of Gaia Botanicals) is a party to the non-compete, non-solicitation, and non-disparagement agreements.

Stakeholder Impact

• Shareholders (cbdMD): Potential for long-term value creation through brand expansion and revenue growth, but also potential dilution from share issuance.
• Shareholders (Gaia Botanicals/Seller): Receive cbdMD common stock as consideration, with future value tied to cbdMD's stock performance and the earnout achievement.
• Employees (Gaia Botanicals): Five active employees will receive employment offers from cbdMD.
• Customers (Bluebird Botanicals): Continued access to Bluebird Botanicals products and information, potentially enhanced by cbdMD's resources.
• Suppliers (Bluebird Botanicals): Existing relationships may transition to cbdMD.

Next Steps

• Integration of Bluebird Botanicals' assets, brand, and online marketplace into cbdMD's operations.
• Issuance of up to 525,000 Earnout Shares to Gaia Botanicals based on Net Revenue performance over the next year.
• cbdMD to spend at least $90,000 per quarter on marketing, advertising, and online traffic for the Bluebird Brand.
• Employment offers to be extended to five active employees of Gaia Botanicals.
• Seller and Brandon Beatty to adhere to five-year non-compete, non-solicitation, and non-disparagement covenants.

Key Dates

Recommendation

The acquisition of Bluebird Botanicals is a strategic positive for cbdMD, expanding its brand portfolio and market reach within the CBD sector. The earnout structure aligns incentives for growth, and the non-compete provisions are favorable. However, the immediate impact on cbdMD's financial performance is yet to be seen, and the potential for share dilution from the earnout shares warrants a 'hold' stance until more clarity on integration success and financial results emerges. The market's reaction to the dilution and the ability to meet earnout targets will be key determinants for future performance.

Keywords

cbdMD, Gaia Botanicals, Bluebird Botanicals, Asset Purchase Agreement, CBD, Acquisition, Earnout, Lock-Up Agreement, Restricted Stock, Cannabis Industry, Hemp Products, Intellectual Property, Corporate Governance, SEC Filing, 8-K